埃格列净对2型糖尿病合并动脉粥样硬化性心血管疾病患者心力衰竭相关事件的疗效:VERTIS CV试验结果
VERTIS CV试验将8246例2型糖尿病合并动脉粥样硬化性心血管疾病患者随机分配至埃格列净5mg、15mg或安慰剂组。预设二次分析显示,埃格列净未显著降低首次心力衰竭住院(HHF)或心血管死亡复合终点(HR 0.88,95%CI 0.75-1.03),但显著降低首次HHF风险(HR 0.70,95%CI 0.54-0.90;P=0.006)以及HHF总事件和HHF/心血管死亡总事件。
要点
- 埃格列净未显著降低首次HHF/心血管死亡复合终点。
- 埃格列净显著降低首次HHF风险(HR 0.70,95%CI 0.54-0.90;P=0.006)。
- 埃格列净减少HHF总事件和HHF/心血管死亡总事件。
核心结论
- 在2型糖尿病合并动脉粥样硬化性心血管疾病患者中,埃格列净降低首次和总HHF风险以及总HHF/心血管死亡,支持SGLT2抑制剂用于HHF的一级和二级预防。
研究设计与样本
- VERTIS CV为双盲、安慰剂对照试验,随机分配8246例2型糖尿病合并动脉粥样硬化性心血管疾病患者至埃格列净5mg、15mg或安慰剂每日一次。
主要发现
- 埃格列净未显著减少首次HHF/心血管死亡(HR 0.88,95%CI 0.75-1.03)。
- 埃格列净减少首次HHF(HR 0.70,95%CI 0.54-0.90;P=0.006),既往心衰史未改变此效应(P交互=0.40)。
- 在总体人群中,EF≤45%者首次HHF风险降低幅度 tended greater(HR 0.48,95%CI 0.30-0.76) versus EF>45%者(HR 0.86,95%CI 0.58-1.29)。
- 基线eGFR<60 mL·min-1·1.73 m-2、白蛋白尿和使用利尿剂三个亚组中埃格列净获益更明显(各P交互<0.05)。
- 埃格列净减少HHF总事件(率比0.70,95%CI 0.56-0.87)和HHF/心血管死亡总事件(率比0.83,95%CI 0.72-0.96)。
临床怎么用
- 对于2型糖尿病合并动脉粥样硬化性心血管疾病患者,可考虑使用埃格列净以降低HHF风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of ertugliflozin on HHF and related outcomes. METHODS: VERTIS CV (Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial), a double-blind, placebo-controlled trial, randomly assigned patients with type 2 diabetes mellitus and atherosclerotic cardiovascular (CV) disease to once-daily ertugliflozin 5 mg, 15 mg, or placebo. Prespecified secondary analyses compared ertugliflozin (pooled doses) versus placebo on time to first event of HHF and composite of HHF/CV death, overall and stratified by prespecified characteristics. Cox proportional hazards modeling was used with the Fine and Gray method to account for competing mortality risk, and Andersen-Gill modeling to analyze total (first+recurrent) HHF and total HHF/CV death events. RESULTS: A total of 8246 patients were randomly assigned to ertugliflozin (n=5499) or placebo (n=2747); n=1958 (23.7%) had a history of heart failure (HF) and n=5006 (60.7%) had pretrial ejection fraction (EF) available, including n=959 with EF ≤45%. Ertugliflozin did not significantly reduce first HHF/CV death (hazard ratio [HR], 0.88 [95% CI, 0.75-1.03]). Overall, ertugliflozin reduced risk for first HHF (HR, 0.70 [95% CI, 0.54-0.90]; P=0.006). Previous HF did not modify this effect (HF: HR, 0.63 [95% CI, 0.44-0.90]; no HF: HR, 0.79 [95% CI, 0.54-1.15]; P interaction=0.40). In patients with HF, the risk reduction for first HHF was similar for those with reduced EF ≤45% versus preserved EF >45% or unknown. However, in the overall population, the risk reduction tended to be greater for those with EF ≤45% (HR, 0.48 [95% CI, 0.30-0.76]) versus EF >45% (HR, 0.86 [95% CI, 0.58-1.29]). Effect on risk for first HHF was consistent across most subgroups, but greater benefit of ertugliflozin was observed in 3 populations: baseline estimated glomerular filtration rate <60 mL·min-1·1.73 m-2, albuminuria, and diuretic use (each P interaction <0.05). Ertugliflozin reduced total events of HHF (rate ratio, 0.70 [95% CI, 0.56-0.87]) and total HHF/CV death (rate ratio, 0.83 [95% CI, 0.72-0.96]). CONCLUSIONS: In patients with type 2 diabetes mellitus, ertugliflozin reduced the risk for first and total HHF and total HHF/CV death, adding further support for the use of sodium-glucose cotransporter 2 inhibitors in primary and secondary prevention of HHF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01986881.
引用
- Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020. PMID: 33026243. doi:10.1161/CIRCULATIONAHA.120.050255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。